OncoCyte Price To Sales Ratio vs Free Cash Flow Yield Analysis

OCX Stock

USD 2.44 0.09 3.56%

OncoCyte Corp financial indicator trend analysis is much more than just breaking down OncoCyte Corp prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether OncoCyte Corp is a good investment. Please check the relationship between OncoCyte Corp Price To Sales Ratio and its Free Cash Flow Yield accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OncoCyte Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.

Price To Sales Ratio vs Free Cash Flow Yield

Price To Sales Ratio vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of OncoCyte Corp Price To Sales Ratio account and Free Cash Flow Yield. At this time, the significance of the direction appears to have very strong relationship.

The correlation between OncoCyte Corp's Price To Sales Ratio and Free Cash Flow Yield is 0.85. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of OncoCyte Corp, assuming nothing else is changed. The correlation between historical values of OncoCyte Corp's Price To Sales Ratio and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of OncoCyte Corp are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Price To Sales Ratio i.e., OncoCyte Corp's Price To Sales Ratio and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

0.85

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing OncoCyte Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on OncoCyte Corp sales, a figure that is much harder to manipulate than other OncoCyte Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from OncoCyte Corp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into OncoCyte Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OncoCyte Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.At this time, OncoCyte Corp's Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 117.1 K in 2024, whereas Discontinued Operations is likely to drop (51.3 M) in 2024.

OncoCyte Corp fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment
Total Assets		0.41	0.91	0.89	0.95	0.91	-0.8	-0.75	0.98	0.86	0.99	0.57	0.08	0.85	0.77	0.68	-0.55	0.95	-0.42	0.98	0.91	0.88	-0.04	0.93	0.8	0.82
Short Long Term Debt Total	0.41		0.27	0.55	0.52	0.48	-0.06	-0.25	0.27	0.27	0.43	0.51	0.64	0.26	0.28	0.22	-0.24	0.36	0.02	0.32	0.48	0.27	0.58	0.28	0.3	0.41
Other Current Liab	0.91	0.27		0.89	0.84	0.92	-0.77	-0.77	0.91	0.8	0.9	0.39	-0.16	0.77	0.77	0.69	-0.67	0.94	-0.48	0.91	0.92	0.82	-0.2	0.87	0.8	0.78
Total Current Liabilities	0.89	0.55	0.89		0.8	0.86	-0.57	-0.67	0.85	0.67	0.91	0.47	0.11	0.66	0.67	0.57	-0.44	0.92	-0.42	0.91	0.86	0.71	0.27	0.84	0.7	0.73
Total Stockholder Equity	0.95	0.52	0.84	0.8		0.88	-0.82	-0.68	0.91	0.9	0.93	0.59	0.23	0.89	0.71	0.63	-0.59	0.89	-0.28	0.88	0.88	0.91	-0.1	0.84	0.74	0.79
Property Plant And Equipment Net	0.91	0.48	0.92	0.86	0.88		-0.67	-0.81	0.88	0.75	0.91	0.62	0.0	0.72	0.81	0.73	-0.64	0.9	-0.57	0.88	1.0	0.78	-0.09	0.83	0.84	0.86
Net Debt	-0.8	-0.06	-0.77	-0.57	-0.82	-0.67		0.54	-0.85	-0.98	-0.72	-0.24	0.09	-0.97	-0.56	-0.5	0.62	-0.78	0.2	-0.74	-0.67	-0.96	0.44	-0.74	-0.6	-0.56
Retained Earnings	-0.75	-0.25	-0.77	-0.67	-0.68	-0.81	0.54		-0.76	-0.6	-0.77	-0.52	0.35	-0.53	-1.0	-0.99	0.76	-0.66	0.83	-0.76	-0.81	-0.58	0.26	-0.88	-0.99	-0.97
Accounts Payable	0.98	0.27	0.91	0.85	0.91	0.88	-0.85	-0.76		0.88	0.96	0.48	-0.06	0.87	0.78	0.69	-0.56	0.94	-0.48	0.98	0.88	0.9	-0.14	0.93	0.8	0.8
Cash	0.86	0.27	0.8	0.67	0.9	0.75	-0.98	-0.6	0.88		0.79	0.35	0.04	0.99	0.63	0.55	-0.66	0.83	-0.21	0.79	0.75	0.99	-0.3	0.78	0.66	0.65
Non Current Assets Total	0.99	0.43	0.9	0.91	0.93	0.91	-0.72	-0.77	0.96	0.79		0.59	0.08	0.78	0.78	0.7	-0.52	0.94	-0.46	0.98	0.91	0.82	0.02	0.93	0.81	0.84
Non Currrent Assets Other	0.57	0.51	0.39	0.47	0.59	0.62	-0.24	-0.52	0.48	0.35	0.59		0.48	0.37	0.54	0.47	-0.13	0.47	-0.36	0.52	0.62	0.4	0.11	0.53	0.54	0.61
Other Assets	0.08	0.64	-0.16	0.11	0.23	0.0	0.09	0.35	-0.06	0.04	0.08	0.48		0.11	-0.3	-0.38	0.38	0.05	0.56	-0.01	0.0	0.08	0.56	-0.13	-0.28	-0.16
Cash And Short Term Investments	0.85	0.26	0.77	0.66	0.89	0.72	-0.97	-0.53	0.87	0.99	0.78	0.37	0.11		0.57	0.48	-0.55	0.84	-0.17	0.78	0.72	0.99	-0.25	0.77	0.6	0.59
Common Stock Total Equity	0.77	0.28	0.77	0.67	0.71	0.81	-0.56	-1.0	0.78	0.63	0.78	0.54	-0.3	0.57		0.99	-0.76	0.67	-0.8	0.77	0.81	0.61	-0.25	0.9	1.0	0.98
Common Stock Shares Outstanding	0.68	0.22	0.69	0.57	0.63	0.73	-0.5	-0.99	0.69	0.55	0.7	0.47	-0.38	0.48	0.99		-0.77	0.57	-0.82	0.68	0.73	0.52	-0.3	0.84	0.98	0.96
Short Term Investments	-0.55	-0.24	-0.67	-0.44	-0.59	-0.64	0.62	0.76	-0.56	-0.66	-0.52	-0.13	0.38	-0.55	-0.76	-0.77		-0.47	0.45	-0.5	-0.64	-0.56	0.47	-0.61	-0.77	-0.72
Other Current Assets	0.95	0.36	0.94	0.92	0.89	0.9	-0.78	-0.66	0.94	0.83	0.94	0.47	0.05	0.84	0.67	0.57	-0.47		-0.39	0.95	0.9	0.88	-0.01	0.87	0.71	0.72
Other Stockholder Equity	-0.42	0.02	-0.48	-0.42	-0.28	-0.57	0.2	0.83	-0.48	-0.21	-0.46	-0.36	0.56	-0.17	-0.8	-0.82	0.45	-0.39		-0.5	-0.57	-0.24	0.18	-0.61	-0.79	-0.74
Total Liab	0.98	0.32	0.91	0.91	0.88	0.88	-0.74	-0.76	0.98	0.79	0.98	0.52	-0.01	0.78	0.77	0.68	-0.5	0.95	-0.5		0.88	0.82	0.0	0.94	0.79	0.8
Property Plant And Equipment Gross	0.91	0.48	0.92	0.86	0.88	1.0	-0.67	-0.81	0.88	0.75	0.91	0.62	0.0	0.72	0.81	0.73	-0.64	0.9	-0.57	0.88		0.78	-0.09	0.83	0.84	0.86
Total Current Assets	0.88	0.27	0.82	0.71	0.91	0.78	-0.96	-0.58	0.9	0.99	0.82	0.4	0.08	0.99	0.61	0.52	-0.56	0.88	-0.24	0.82	0.78		-0.24	0.8	0.65	0.64
Short Term Debt	-0.04	0.58	-0.2	0.27	-0.1	-0.09	0.44	0.26	-0.14	-0.3	0.02	0.11	0.56	-0.25	-0.25	-0.3	0.47	-0.01	0.18	0.0	-0.09	-0.24		-0.1	-0.24	-0.16
Intangible Assets	0.93	0.28	0.87	0.84	0.84	0.83	-0.74	-0.88	0.93	0.78	0.93	0.53	-0.13	0.77	0.9	0.84	-0.61	0.87	-0.61	0.94	0.83	0.8	-0.1		0.91	0.9
Common Stock	0.8	0.3	0.8	0.7	0.74	0.84	-0.6	-0.99	0.8	0.66	0.81	0.54	-0.28	0.6	1.0	0.98	-0.77	0.71	-0.79	0.79	0.84	0.65	-0.24	0.91		0.99
Property Plant Equipment	0.82	0.41	0.78	0.73	0.79	0.86	-0.56	-0.97	0.8	0.65	0.84	0.61	-0.16	0.59	0.98	0.96	-0.72	0.72	-0.74	0.8	0.86	0.64	-0.16	0.9	0.99

Click cells to compare fundamentals

OncoCyte Corp Account Relationship Matchups

OncoCyte Corp fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	39.9M	55.4M	159.6M	100.1M	74.9M	49.1M
Short Long Term Debt Total	5.9M	8.6M	5.7M	3.5M	2.9M	4.1M
Other Current Liab	2.6M	5.3M	9.4M	9.2M	4.9M	4.7M
Total Current Liabilities	4.4M	9.0M	14.1M	12.1M	7.2M	7.6M
Total Stockholder Equity	30.8M	33.5M	65.2M	34.3M	25.6M	22.0M
Property Plant And Equipment Net	3.7M	6.5M	8.5M	10.9M	5.4M	3.8M
Net Debt	(16.1M)	1.5M	(29.9M)	(16.4M)	(6.6M)	(6.9M)
Retained Earnings	(93.7M)	(123.7M)	(187.8M)	(260.7M)	(289.9M)	(275.4M)
Accounts Payable	469K	432K	1.8M	1.3M	953K	621.2K
Cash	22.1M	7.1M	35.6M	20.0M	9.4M	12.8M
Non Current Assets Total	16.9M	46.2M	120.4M	74.6M	64.2M	33.5M
Non Currrent Assets Other	2.2M	1.9M	2.0M	2.1M	2.2M	1.5M
Other Assets	2.2M	2.1M	2.0M	1.0	1.15	1.09
Cash And Short Term Investments	22.5M	7.8M	36.5M	20.4M	9.4M	14.5M
Common Stock Total Equity	124.6M	157.2M	253.0M	294.9M	339.2M	356.1M
Common Stock Shares Outstanding	2.6M	3.3M	4.4M	5.5M	7.7M	8.0M
Short Term Investments	428K	379K	675K	904K	433K	0.0
Liabilities And Stockholders Equity	39.9M	55.4M	159.6M	100.1M	74.9M	49.1M
Other Current Assets	505K	1.2M	3.9M	3.1M	782K	1.1M
Other Stockholder Equity	948K	343K	37K	(5.3M)	(4.8M)	(4.5M)
Total Liab	9.0M	21.9M	94.3M	65.8M	49.3M	27.1M
Property Plant And Equipment Gross	3.7M	6.5M	8.5M	10.9M	5.4M	3.8M
Total Current Assets	23.0M	9.2M	39.1M	25.5M	10.7M	15.7M
Accumulated Other Comprehensive Income	(343K)	0.0	37K	39K	49K	51.5K
Short Term Debt	1.4M	3.2M	3.0M	1.6M	1.3M	1.7M
Common Stock	124.6M	157.2M	253.0M	294.9M	310.3M	325.8M
Property Plant Equipment	614K	3.7M	6.5M	8.5M	9.8M	10.3M
Net Tangible Assets	30.8M	9.3M	(44.7M)	(22.0M)	(19.8M)	(18.8M)
Long Term Debt	1.1M	347K	1.9M	1.5M	1.7M	905.1K
Retained Earnings Total Equity	(93.7M)	(123.7M)	(187.8M)	(260.7M)	(234.6M)	(222.9M)
Long Term Debt Total	1.4M	534K	2.0M	1.5M	1.7M	1.2M
Non Current Liabilities Total	4.6M	12.9M	80.2M	53.7M	42.1M	26.9M
Capital Lease Obligations	2.9M	4.7M	4.4M	3.5M	2.9M	2.8M
Net Invested Capital	33.9M	37.4M	66.5M	34.3M	20.5M	32.0M
Net Working Capital	18.5M	230K	25.0M	13.4M	3.5M	3.3M
Capital Stock	124.6M	157.2M	253.0M	294.9M	310.3M	222.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for OncoCyte Stock Analysis

When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

OncoCyte Price To Sales Ratio vs Free Cash Flow Yield Analysis

Price To Sales Ratio vs Free Cash Flow Yield

Price To Sales Ratio vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Free Cash Flow Yield

OncoCyte Corp fundamental ratios Correlations

OncoCyte Corp Account Relationship Matchups

High Positive Relationship

High Negative Relationship

OncoCyte Corp fundamental ratios Accounts

Also Currently Popular

Additional Tools for OncoCyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 1.0	Common Stock Total Equity
Non Current Assets Total	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments

Common Stock Total Equity	- 1.0	Retained Earnings
Common Stock	- 0.99	Retained Earnings
Common Stock Shares Outstanding	- 0.99	Retained Earnings
Cash	- 0.98	Net Debt
Property Plant Equipment	- 0.97	Retained Earnings
Cash And Short Term Investments	- 0.97	Net Debt